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Are we at risk of being at risk? That is the question posed by 
the editor of the British Medical Journal in a recent issue1 
about the substantial influence of the pharmaceutical 
industry over health care decisions being made by doctors in 
America. The issue introduced by BMJ brings to light the 
considerable need to analyze the effects of said influence on 
health care as a whole.  Close attention must be paid to the 
symbiotic, and potentially detrimental, relationship taking 
place between medical doctors and pharmaceutical 
companies in terms of financial incentives; doctors with such 
financial ties will more than likely prescribe the companies’ 
drugs to their patients whether these drugs are truly 
necessary or not. As future healthcare professionals, we must 
take this into consideration because a relationship like this 
one can result in millions of people taking unnecessary drugs 
due to the powerful influence of industry. This is the message 
being conveyed by Ray Moynihan, an Australian health 
journalist and author who set out to explore this viewpoint 
with his latest book, Sex, Lies and Pharmaceuticals: How Drug 
Companies Plan to Profit From Female Sexual Dysfunction.2 
During a stimulating and insightful lecture, Moynihan 
discussed the many financial ties between the 
pharmaceutical industry and doctors as well as the adverse 
influence the former have over the latter.  
 
According to Moynihan’s lecture, Female Sexual Dysfunction 
(FSD) is defined by the pharmaceutical industry as a disorder 
of desire, arousal, orgasm and pain. Many studies had been 
conducted to assess the prevalence of FSD with resulting 
claims that up to 50% of women suffered from it. 3 A survey 
asking questions such as “Do you ever lack interest in sex?” 
and “Do you have trouble getting aroused?” was given to a 
group of women, and, if any single question was answered 
with “yes,” the women were diagnosed with FSD. That 
doesn’t seem too accurate or believable, but this was 
perceived to be a legitimate disorder for some time. The 
Journal of Sexual Medicine later published an article about 
decreased sexual desire in females, and the study was funded 
by the pharmaceutical company, Boehringer Ingelheim (BI). 4   
In addition, one third of the study researchers were 
employees of BI, and the lead author of the study had 
financial ties to at least ten pharmaceutical companies—
perhaps a major red flag when it comes to conflicts of  
interest? Celebrity spokespeople were endorsing drugs 
indicated for FSD while there were no unbiased studies in 
existence that proved this “disorder” was a major problem; 
non industry-funded studies showed different results. 
 
Though pharmaceutical companies clearly have financial 
motives for marketing their own products, it may not be fair 
to completely write off their providing funding for some 
studies. In the testing process, studies can potentially lead to 
the discovery of information that may prove to be beneficial 
for the general public. Consider the example of a study that 
concludes that Drug X is efficacious for an additional disease 
state, or that the drug can be used safely in patients for a 
longer period of time. The manufacturer would definitely 
benefit from this study's creating an expanded need for the 
drug, even increasing patent life and exclusivity.  At the same 
time, there may be patients who can potentially benefit from 
such evidence as well.  However, this information—
particularly if it discredits a product—may not be made as 
readily available and herein presents the battle of the ethical 
and financial incentives. Moynihan’s main point spoke to the 
overwhelming need for both the healthcare system and 
healthcare professionals to reestablish independence from 
the influence of pharmaceutical companies that habitually 
put profits ahead of the best interests of their customers: the 
public. 
 
This issue ought to raise questions in everyone’s minds, 
especially those of us whose future career is tied to the 
public’s use of prescription drugs. A fundamental question 
should be asked: who is funding these studies? Clearly, the 
testing of new expensive drugs requires money for resources 
such as study materials, personnel, and of course, the drugs 
that are being evaluated. Since manufacturers invest money 
in a process or product in the hope of securing a profitable 
future, the potential of this bias affecting the presentation 
and thus validity of the results must be critically explored. 
 
Similarly, it is important to ponder the question of who would 
benefit from study conclusions.  While evaluating a study to 
consider how findings will affect clinical practice, it is 
necessary and important to consider how the study 
conclusions will affect the industry, third-party payers, and  
potentially treatment guidelines that may shape medical 
practice itself. Hence, another related question emerges: 
what studies are used by the experts to write the practice 
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guidelines, and do these experts have any conflicting 
interests?  
 
Another aspect to add to this list of questions is the 
increasing emergence of “me-too” drugs. Where are these 
new drugs coming from? It could be the product of years of 
new research, or the product of a slight change in chemical 
structure that allows it to be classified as a “new” drug. As we 
take a closer look at the nation’s healthcare spending, it 
warrants our concern of adding drugs to the market that 
actually provide breakthrough treatment option for 
burdensome diseases instead of adding to an existing cohort 
of options that all perform similarly. Does the world really 
need another proton pump inhibitor or SSRI? A potential 
challenge now is to increase market share and convince both 
patients and the prescribers that a new drug is worth the 
added cost. 
 
We are all witness to television commercials for a drug that 
seemingly turns a person’s life around from black-and-white 
depression to sunshine and rainbows in beautiful fields of 
grass. People are holding hands with ear-to-ear grins or 
kayaking after taking this brand new drug; the celebrity 
endorser of the drug is quick to imply that if it worked for 
them, it will definitely work for you or your patient, albeit 
people respond to these commercials in different ways. Some 
will immediately speak to their doctor about wanting to try 
this fabulous new drug that can be the magic cure for the 
ailment they just diagnosed themselves with. Some will 
wonder whether the information in the commercial is 
believable and trustworthy or if this is just another 
advertising technique of the pharmaceutical industry to make 
more money. Yet others may opine that the benefits of Direct 
to Consumer advertising can help increase patient awareness 
of the existence of possible treatment and give patients more 
incentive to visit their doctors and discuss whether the drug 
may be right for them; if consumers become more informed 
about their health condition from a commercial, they will 
likely seek medical care and therefore improve the quality of 
their health. However, with overwhelming health care costs 
burdening the country’s economy, we must consider the 
universal effects of DTC advertising. Billions of dollars are 
spent on pharmaceutical advertising annually, which then 
directly contributes to the amount of money spent on 
prescriptions. What if that money were spent on programs 
promoting preventative care or medication therapy 
management? If pharmaceutical companies chose to shift 
their focus from gaining profits to improving the health of 
their consumers, this would definitely be a major step in the 
direction health care has been trying to move towards: better 
quality care at a lower cost in the long-run.  
 
When the top story on the evening news is about a 
groundbreaking study that was just published, it is our duty 
to ask questions and delve further into the details of how the 
study was done and who had particular interests in it. 
Unfortunately, as it is now, there is arguably not enough 
understanding of application of literature evaluation and how 
treatment guidelines are established. Perhaps we could 
explore more balanced discussions about a pharmaceutical 
industry that directly affects pharmacists and student 
pharmacists alike. Though this is not a new topic, as student 
pharmacists, we witness how new drug marketing and 
published literature can be biased and warrants that we be 
conscious of this in our daily learning. Fortunately, there is a 
wealth of information and books available on the topics, and 
like in any discipline, deeper learning requires going beyond 
what is presented in the curriculum and seeking outside 
knowledge to enhance classroom teaching. It is in this way 
that we become more aware and able to educate ourselves, 
each other, and the public. By encouraging debate, we can 
change perception and bring change. Recently, Boehringer 
Ingelheim announced a halt to research on “female Viagra.” 
This is a small, yet encouraging victory, and further triumphs 
will be dependent on the efforts of us future healthcare 
professionals. So here is one last question to think about: 
from inception to marketing, and from marketing to media, 
where do we fit into this risky business? 
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